Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global acute ischemic stroke therapeutics market. The report identifies the key trends shaping and driving the global acute ischemic stroke therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global acute ischemic stroke therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the acute ischemic stroke market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) acute ischemic stroke therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as immunomodulators, NMDA receptor antagonists, platelet inhibitor, polyketide antibiotics, and recombinant proteins amongst others.
• Analysis of the current and future competition in the seven key countries acute ischemic stroke therapeutics market. Key market players covered are Celgene Corporation, Cidat C.V. Corrimum Gmbh, D-Pharm Ltd., H Lundbeck A/S, Mitsubhishi Tanabe Pharma, Panacea Pharmaceuticals, Pfizer, Inc., Sanofi, Stemedica Cell Technologies, Vernalis PLC.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the acute ischemic stroke market.
• Analysis of key recent licensing and partnership agreements in acute ischemic stroke therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global acute ischemic stroke market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global acute ischemic stroke market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global acute ischemic stroke market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Acute Ischemic Stroke Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.3.1 Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Treatment and Management Options
2.6.1 Referral Pathway
2.7 GlobalData Pipeline Report Guidance

3 Acute Ischemic Stroke Therapeutics - Market Characterization
3.1 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - Global
3.2 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - Global
3.3 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - The US
3.4 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - The US
3.5 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - France
3.6 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - France
3.7 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - Germany
3.8 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - Germany
3.9 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - Italy
3.10 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - Italy
3.11 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - Spain
3.12 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - Spain
3.13 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - The UK
3.14 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - The UK
3.15 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - Japan
3.16 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the Acute Ischemic Stroke Therapeutics Market
3.17.1 Drivers for the Acute Ischemic Stroke Therapeutics Market
3.17.2 Barriers for the Acute Ischemic Stroke Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway

4 Acute Ischemic Stroke Therapeutics - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Product Profiles for the Major Marketed Products in the Acute Ischemic Stroke Therapeutics Market
4.2.1 Activase (alteplase)
4.2.2 Plavix (clopidogrel)
4.2.3 Radicut (edaravone)
4.3 Key Takeaway

5 Acute Ischemic Stroke Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Acute Ischemic Stroke Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Acute Ischemic Stroke Therapeutics - Filed Pipeline
5.3.2 Acute Ischemic Stroke Therapeutics - Phase III Pipeline
5.3.3 Acute Ischemic Stroke Therapeutics - Phase II Pipeline
5.3.4 Acute Ischemic Stroke Therapeutics - Phase I Pipeline
5.3.5 Acute Ischemic Stroke Therapeutics - Pre-Clinical Pipeline
5.3.6 Acute Ischemic Stroke Therapeutics - Discovery Pipeline
5.3.7 Technology Trends Analytical Framework
5.4 Acute Ischemic Stroke Therapeutics Market - Pipeline by Mechanism of Action
5.5 Phase III Drugs Under Development
5.5.1 Desmoteplase
5.5.2 DP-b99
5.5.3 Dapsone
5.6 Key Takeaway

6 Acute Ischemic Stroke Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Acute Ischemic Stroke Therapeutics Clinical Trials

7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Acute Ischemic Stroke Therapeutics - Implications for Future Market Competition

8 Acute Ischemic Stroke Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 H Lundbeck A/S
8.2.2 D-Pharm, Ltd.
8.2.3 Aldagen, Inc.
8.2.4 Celgene Corparation
8.2.5 M’s Science Corporation
8.2.6 Mitsubishi Tanabe Pharma Corporation
8.2.7 SYGNIS Pharma AG
8.2.8 Stemedica Cell Technologies, Inc.
8.2.9 Thrombotech Technologies Ltd.
8.2.10 Vernalis PLC
8.3 Other Companies in the Pipeline

9 Acute Ischemic Stroke Therapeutics - Licensing and Partnership Deals

10 Acute Ischemic Stroke Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

List of Tables

Table 1: Vascular Supply to the Brain
Table 2: Stroke Statistics (2003-2007), The US
Table 3: Initial Management of Ischemic Stroke
Table 4: The National Institutes of Health Stroke Scale
Table 5: Criteria for Thrombolysis of Patients with Acute Ischemic Stroke using rtPA
Table 6: Recommendations for the Use of Anti-Coagulant and Anti-Platelet Agents in Patients with Acute Ischemic Stroke
Table 7: Acute Ischemic Stroke Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Table 8: Acute Ischemic Stroke Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Table 9: Acute Ischemic Stroke Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Table 10: Acute Ischemic Stroke Therapeutics Market, The US, Forecasts ($m), 2010 - 2018
Table 11: Acute Ischemic Stroke Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 12: Acute Ischemic Stroke Therapeutics Market, France, Forecasts ($m), 2010 - 2018
Table 13: Acute Ischemic Stroke Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 14: Acute Ischemic Stroke Therapeutics Market, Germany, Forecasts ($m), 2010 - 2018
Table 15: Acute Ischemic Stroke Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 16: Acute Ischemic Stroke Therapeutics Market, Italy, Forecasts ($m), 2010 - 2018
Table 17: Acute Ischemic Stroke Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 18: Acute Ischemic Stroke Therapeutics Market, Spain, Forecasts ($m), 2010 - 2018
Table 19: Acute Ischemic Stroke Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Table 20: Acute Ischemic Stroke Therapeutics Market, The UK, Forecasts ($m), 2010 - 2018
Table 21: Acute Ischemic Stroke Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 22: Acute Ischemic Stroke Therapeutics Market, Japan, Forecasts ($m), 2010 - 2018
Table 23: Outcome Events in CAPRIE Primary Analysis
Table 24: Edaravone - Efficacy in Acute Ischemic Stroke Patients - Randomized, Placebo-Controlled Study
Table 25: Acute Ischemic Stroke Therapeutics, Filed Pipeline, 2011
Table 26: Acute Ischemic Stroke Therapeutics, Phase III Pipeline, 2011
Table 27: Acute Ischemic Stroke Therapeutics, Phase II Pipeline, 2011
Table 28: Acute Ischemic Stroke Therapeutics, Phase I Pipeline, 2011
Table 29: Acute Ischemic Stroke Therapeutics, Pre-Clinical Pipeline, 2011
Table 30: Acute Ischemic Stroke Therapeutics, Discovery Pipeline, 2011
Table 31: Mechanisms of Action that Constitute the “Others” in the Pipeline
Table 32: Acute Ischemic Stroke Therapeutics, Clinical Trials by Country, 2011
Table 33: Acute Ischemic Stroke Therapeutics, Clinical Trials by Phase, 2011
Table 34: Acute Ischemic Stroke Therapeutics, Overall Sponsors, 2011
Table 35: Acute Ischemic Stroke Therapeutics, Prominent Sponsors, 2011
Table 36: Acute Ischemic Stroke Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 37: H. Lundbeck A/S, Inflammatory and Infectious Diseases, Pipeline, 2011
Table 38: H. Lundbeck A/S, Acute Ischemic Stroke, Pipeline, 2011
Table 39: D-Pharm Ltd., CNS Pipeline, 2011
Table 40: D-Pharm Ltd., Acute Ischemic Stroke Pipeline, 2011
Table 41: Aldagen, Inc., CNS Pipeline, 2011
Table 42: Aldagen, Inc., Acute Ischemic Stroke Pipeline, 2011
Table 43: Celgene Corporation, CNS Pipeline, 2011
Table 44: Celgene Corporation, Acute Ischemic Stroke Pipeline, 2011
Table 45: M’s Science Corporation, CNS Pipeline, 2011
Table 46: M’s Science Corporation, Acute Ischemic Stroke Pipeline, 2011
Table 47: Mitsubishi Tanabe Pharma Corporation, CNS Pipeline, 2011
Table 48: Mitsubishi Tanabe Pharma Corporation, CNS Pipeline, 2011
Table 49: SYGNIS Pharma AG, Acute Ischemic Stroke Pipeline, 2011
Table 50: SYGNIS Pharma AG, Acute Ischemic Stroke Pipeline, 2011
Table 51: SYGNIS Pharma AG, Acute Ischemic Stroke Pipeline, 2011
Table 52: Thrombotech Technologies, Acute Ischemic Stroke Pipeline, 2011
Table 53: Vernalis PLC, CNS Pipeline, 2011
Table 54: Vernalis PLC, Acute Ischemic Stroke Pipeline, 2011
Table 55: Acute Ischemic Stroke Therapeutics, Other Companies in the Pipeline
Table 56: Acute Ischemic Stroke Therapeutics, Deals, 2008-2011

List of Figures

Figure 1: Causes of Ischemic Stroke
Figure 2: Axial Non-contrast Computed Tomography (NCCT) Showing Diffuse Hypodensity in the Brain
Figure 3: Acute Ischemic Stroke Therapeutics, Algorithm for the Management of Patients with Acute Ischemic Stroke
Figure 4: Acute Ischemic Stroke Therapeutics, Treatment Protocol
Figure 5: Acute Ischemic Stroke Therapeutics, Treatment Algorithm
Figure 6: Acute Ischemic Stroke Therapeutics, Stroke Code for the Treatment of Acute Ischemic Stroke
Figure 7: Acute Ischemic Stroke, Referral Pathway
Figure 8: Acute Ischemic Stroke Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Figure 9: Acute Ischemic Stroke Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Figure 10: Acute Ischemic Stroke Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Figure 11: Acute Ischemic Stroke Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Figure 12: Acute Ischemic Stroke Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 13: Acute Ischemic Stroke Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 14: Acute Ischemic Stroke Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 15: Acute Ischemic Stroke Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Figure 16: Acute Ischemic Stroke Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 17: Acute Ischemic Stroke Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 18: Acute Ischemic Stroke Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 19: Acute Ischemic Stroke Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 20: Acute Ischemic Stroke Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Figure 21: Acute Ischemic Stroke Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Figure 22: Acute Ischemic Stroke Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 23: Acute Ischemic Stroke Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 24: Opportunity and Unmet Need in the Acute Ischemic Stroke Therapeutics Market, Primary Treatment, 2010
Figure 25: Opportunity and Unmet Need in the Acute Ischemic Stroke Therapeutics Market, Maintenance Therapy, 2010
Figure 26: Acute Ischemic Stroke Therapeutics, Strategic Competitor Assessment, 2010
Figure 27: Acute Ischemic Stroke Therapeutics, Pipeline by Phase of Development, 2011
Figure 28: Acute Ischemic Stroke Therapeutics, Technology Trends Analytics Framework, 2011
Figure 29: Acute Ischemic Stroke Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 30: Acute Ischemic Stroke Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 31: Acute Ischemic Stroke Therapeutics, Clinical Trials by Country, 2011
Figure 32: Acute Ischemic Stroke Therapeutics, Clinical Trials by Phase (%), 2011
Figure 33: Acute Ischemic Stroke Therapeutics, Clinical Trials by Status (%), 2011
Figure 34: Acute Ischemic Stroke Therapeutics, Overall Sponsors (%), 2011
Figure 35: Acute Ischemic Stroke Therapeutics, Prominent Sponsors (%), 2011
Figure 36: Acute Ischemic Stroke Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 37: Acute Ischemic Stroke Therapeutics Market, Drivers and Barriers, 2011
Figure 38: Implications for Future Market Competition in the Acute Ischemic Stroke Market, 2011
Figure 39: Acute Ischemic Stroke Therapeutics Market - Pipeline by Company, 2010